STAR IN THE NEWS​

Press Releases

Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting

  • Purohit Navigation
  • November 3, 2025
SOUTH SAN FRANCISCO, CA, November 3, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today...

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing

  • Purohit Navigation
  • September 30, 2025
SOUTH SAN FRANCISCO, CA, September 30, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing.

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

  • Purohit Navigation
  • January 6, 2025
SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2025
SOUTH SAN FRANCISCO, CA, January 2, 2025 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

  • Purohit Navigation
  • December 9, 2024
SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • June 26, 2024
SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

  • Purohit Navigation
  • January 3, 2024
SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2024
SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

  • Purohit Navigation
  • December 5, 2023
SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

  • Purohit Navigation
  • September 5, 2023
SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...

News Coverage

Star gets $125M Series D as it begins Phase 3 in bleeding disorders

  • Kyle LaHucik, Endpoints News
  • September 30, 2025
Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO Adam Rosenthal told Endpoints News...

Star raises another $125M for its blood disease drug

  • Gwendolyn Wu, BioPharma Dive
  • September 30, 2025
The biotech began Phase 3 testing of an experimental medicine for Von Willebrand disease in early September. Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to build single-drug offshoots, Star is now primarily focused on a singular program for...

Star Therapeutics collects shiny $125M funding boost to push bleeding disorder prospect into orbit

  • Zoey Becker, Fierce Biotech
  • September 30, 2025
A hefty $125 million in new financing has been written in the stars for Star Therapeutics through an oversubscribed series D funding round. The series D was co-led by Sanofi Ventures and Viking Global Investors, with support from over a dozen existing investors including Sofinnova, Blue Owl Capital and RA Capital Management. New investors such as Janus Henderson...

Breaking new ground in von Willebrand disease treatment

  • Jules Adam, Labiotech
  • January 9, 2025
Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...

Presentations

A PHASE IA STUDY OF VGA039, A PROTEIN S–TARGETING MONOCLONAL ANTIBODY, IN INDIVIDUALS WITH VON WILLEBRAND DISEASE DEMONSTRATES CONCENTRATION-DEPENDENT INCREASES IN THROMBIN GENERATION FOR REDUCING BLEEDING

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3981

DIAGNOSIS AND DISEASE BURDEN OF VON WILLEBRAND DISEASE IN A LARGE US POPULATION–BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3980

DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH VON WILLEBRAND DISEASE IN A LARGE US POPULATION-BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3978

Factor VIII Coagulant Activity (FVIII:C) as an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3982